RxDoctor Payments Data
★ My doctorsLook up a doctor →

Stephen Vang, PA

Medical · Sartell, MNNPI 1366755415

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,077 of the $1,215 with a category attached, or 88.6%. Boston Scientific accounts for 61.1% of it on its own, with 7 other manufacturers making up the rest.

$1,215in general payments, 2019–2025

Across 52 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$743
  • Abbott$221
  • Relievant Medsystems, Inc.$113
  • Si-bone, Inc.$37
  • Curonix LLC$36
  • SPR Therapeutics, Inc$32
  • plus $34 from 2 others

What the payments were for

  • Travel & lodging$12410%
  • Food & beverage$1,07789%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific33$743
Abbott11$221
Relievant Medsystems, Inc.2$113
Si-bone, Inc.1$37
Curonix LLC2$36
SPR Therapeutics, Inc1$32
AbbVie1$20
Hikma Pharmaceuticals USA1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,215 in reported general payments places this provider in the 85th percentile of 202 medical providers in Minnesota.

See all medical providers in Minnesota →

Medicare billing

Part B allowed, 2024
$96,521
Medicare patients
222
Services billed
2,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl35$21,926
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen344$9,116
Buprenorphine44$8,924
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen304$8,750
Xtampza ErOxycodone Myristate17$6,390
Oxycodone Hcl249$3,971
Morphine Sulfate ErMorphine Sulfate202$3,954
Gabapentin177$2,692
Fentanyl46$1,620
Tizanidine Hcl111$1,468
Metaxalone11$1,337
Pregabalin54$1,304
Naloxone Hcl15$1,162
Methocarbamol37$309
Cyclobenzaprine Hcl40$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine$14$8,92444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 202 medical providers in Minnesota.

Other medical in Sartell

See the full list for Minnesota →

Where these figures come from

Is this you, or does something look wrong? →